Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BYN-003
- Development stage
- Unknown
- Lead developer
- Bionyra Pharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
BYN-003 (also known as TL-003) is a clinical-stage bispecific monoclonal antibody developed by Bionyra Pharma for the treatment of inflammatory bowel disease (IBD) and other immune-mediated inflammatory diseases. It is designed as a half-life extended (HLE) biologic that simultaneously targets Tumor Necrosis Factor-like Ligand 1A (TL1A) and the p19 subunit of Interleukin-23 (IL-23p19). By inhibiting both the TL1A and IL-23 pathways, BYN-003 aims to provide enhanced efficacy in patients with chronic inflammatory conditions compared to monotherapies. The drug was licensed from TrueLab Biopharmaceutical, with Bionyra holding exclusive global rights outside of Greater China. It entered Phase 1 clinical development in April 2026.
- Other names
- TL-003TL003TL 003
02
Targets
IL23A (Interleukin-23 p19 Subunit)TL1A (TNF-like cytokine 1A)
Beyond the preview
Go deeper on BYN-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BYN-003.